X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DUR-928 (larsucosterol), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.
Lead Product(s): Larsucosterol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
DUR-928 (larsucosterol), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.
Lead Product(s): Larsucosterol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
DUR-928 (larsucosterol), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients.
Lead Product(s): Larsucosterol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 03, 2023
Details:
Larsucosterol (DUR-928) is an endogenous sulfated oxysterol and an epigenetic regulator. Epigenetic regulators are compounds that regulate patterns of gene expression without modifying the DNA sequence.
Lead Product(s): Larsucosterol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
Study comprised enrollment of 300 patients, with 100 patients in each arm for DUR-928 (larsucosterol), inhibits activity of DNMTs, epigenetic enzymes in AH Patients. Primary outcome measure is 90-day survival rate for patients treated with DUR-928 compared to placebo.
Lead Product(s): Larsucosterol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
The potential of epigenetic regulator candidate, larsucosterol (also known as DUR-928) is to improve inflammation, cell death, and tissue regeneration in severe Alcohol-Associated Hepatitis.
Lead Product(s): Larsucosterol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2021
Details:
Larsucosterol (also known as DUR-928), the Company's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in AH patients.
Lead Product(s): Larsucosterol
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Alcohol Abuse and Alcoholism
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021
Details:
Ongoing AHFIRM Phase 2b trial in alcohol-associated hepatitis (AH) patients while we determine next steps for DUR-928 in NASH and explore additional potential acute and chronic indications.
Lead Product(s): DUR-928
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
Phase 1 study assessing the safety, tolerability, pharmacokinetics (PK) of DUR-928 in subjects with moderate (Child-Pugh B scores) and severe (Child-Pugh C scores) hepatic impairment (HI), who received a single oral dose of 200mg DUR-928.
Lead Product(s): DUR-928
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DUR-928
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Details:
POSIMIR is the only approved sustained-release bupivacaine product indicated for up to 72 hours of post-surgical analgesia from a single application.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Posimir
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
